RxDoctor Payments Data

Jennifer Hrivnak

Nurse Practitioner · Puyallup, WANPI 1740531086

Payments from drug & device makers

$3,188in general payments, 2019–2025

Across 179 payments — averaging $17.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$680
  • Novo Nordisk$435
  • Pfizer$219
  • Boehringer Ingelheim$211
  • AstraZeneca$209
  • GSK$204
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,188 in reported general payments places this provider in the 95th percentile of 2,466 nurse practitioner providers in Washington.

See all nurse practitioner providers in Washington

Medicare billing

Part B allowed, 2024
$43,801
Medicare patients
87
Services billed
1,185

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin50$54,613
OzempicSemaglutide26$40,833
TrulicityDulaglutide11$31,137
EliquisApixaban28$24,782
MounjaroTirzepatide22$22,772
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$3,307
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,034
Gabapentin72$1,823
Venlafaxine Hcl ErVenlafaxine Hcl30$1,765
Albuterol Sulfate HfaAlbuterol Sulfate49$1,699
Duloxetine Hcl45$1,649
Pravastatin Sodium82$1,521
Rosuvastatin Calcium45$1,108
Atorvastatin Calcium120$1,065
Omeprazole71$1,063

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$211$54,61350 claims
Lilly USA, LLCTrulicity, Mounjaro$173$53,90933 claims
Novo NordiskOzempic$435$40,83326 claims
PfizerEliquis$219$24,78228 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,466 nurse practitioner providers in Washington.

Other nurse practitioner in Puyallup

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →